Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EuroPCR 2018: Several Studies Add Insight To Best Approach To Stable Coronary Disease, Utility Of FFR

Executive Summary

New clinical data presented at the EuroPCR conference in Paris, including new data from ORBITA, suggest that fractional flow reserve/ instant wave-free ratio-guided percutaneous coronary intervention may produce better long-term outcomes than PCI guided by angiography in terms of mortality, restenosis and stent thrombosis.

You may also be interested in...

AHA 2019: Conservative Approach Works As Well As Intervention For Stable Coronary Disease In ISCHEMIA Trial

The long-awaited results of the ISCHEMIA trial showed that patients with asymptomatic stable coronary disease get no apparent benefit from coronary intervention compared to a more conservative strategy with optimal medical management.

The First Sham-Controlled PCI Trial In Stable Patients

More details about the controversial ORBITA trial.

ACC 2017: Trial Shows FFR-Guidance Can Help Heart Attack Patients Avoid More Revascularizations

Results of the Compare-Acute trial show that STEMI patients benefit from complete revascularization guided by fractional flow reserve measurement, but most of this benefit was driven by the reduction in repeat revascularization. Investigators say more research will be needed to determine if this approach can reduce mortality or other "hard" endpoints.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts